Profile data is unavailable for this security.
About the company
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
- Revenue in USD (TTM)12.31m
- Net income in USD-5.08m
- Incorporated2006
- Employees9.00
- LocationSonoma Pharmaceuticals Inc5445 CONESTOGA COURT, SUITE 150BOULDER 80301United StatesUSA
- Phone+1 (617) 243-0050
- Fax+1 (707) 283-0551
- Websitehttps://sonomapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENDRA Life Sciences Inc | 0.00 | -9.89m | 2.97m | 21.00 | -- | 0.7939 | -- | -- | -1.26 | -1.26 | 0.00 | 0.3388 | 0.00 | -- | -- | 0.00 | -168.89 | -132.00 | -228.29 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Mosaic Immunoengineering Inc | 0.00 | -897.69k | 3.04m | 3.00 | -- | -- | -- | -- | -0.1245 | -0.1245 | 0.00 | -0.8498 | 0.00 | -- | -- | 0.00 | -789.46 | -- | -- | -- | -- | -- | -- | -- | -- | -26.91 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Resonate Blends Inc | 101.41k | -4.72m | 3.13m | 6.00 | -- | -- | -- | 30.82 | -0.0537 | -0.0537 | 0.0012 | -0.0007 | 0.0328 | -- | -- | -- | -152.56 | -680.29 | -- | -- | -34.87 | -78.88 | -4,657.83 | -12,895.26 | -- | -0.7413 | 1.02 | -- | -66.73 | -56.57 | -316.63 | -- | -- | -- |
| Seelos Therapeutics Inc | 1.97m | -27.12m | 3.13m | 10.00 | -- | -- | -- | 1.59 | -44.59 | -44.59 | 2.16 | -17.36 | 0.1449 | -- | 2.24 | 131,600.00 | -198.99 | -180.05 | -- | -386.76 | -- | -- | -1,373.61 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -8.96m | 3.15m | 9.00 | -- | 0.3327 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 3.19m | 9.00 | -- | 0.4186 | -- | 0.2595 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Aditxt Inc | 506.45k | -41.45m | 3.20m | 47.00 | -- | 0.322 | -- | 6.31 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -7.18m | 3.24m | 3.00 | -- | 0.7159 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Optimus Healthcare Services Inc | 1.27m | -7.79m | 3.32m | 17.00 | -- | -- | -- | 2.62 | -0.1948 | -0.1948 | 0.0317 | -0.1291 | 0.2595 | -- | 2.16 | 74,453.53 | -159.79 | -- | -2,228.37 | -- | 77.90 | -- | -615.77 | -- | 0.1525 | -15.41 | 21.18 | -- | -- | -- | -- | -- | -- | -- |
| Livewire Ergogenics Inc | 67.98k | -1.09m | 3.35m | 1.00 | -- | -- | -- | 49.25 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 3.36m | 4.00 | -- | -- | -- | 5.01 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 3.37m | 1.00k | -- | 5.19 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.41m | 25.00 | -- | -- | -- | 0.2159 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 3.41m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Sonoma Pharmaceuticals Inc's reporting currency: US Dollar USD
1.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| G1 Execution Services LLCas of 31 Mar 2024 | 46.05k | 0.30% |
| Geode Capital Management LLCas of 31 Mar 2024 | 35.78k | 0.23% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 24.32k | 0.16% |
| XTX Markets LLCas of 31 Mar 2024 | 16.46k | 0.11% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 13.47k | 0.09% |
| Millennium Management LLCas of 31 Mar 2024 | 13.02k | 0.08% |
| Tower Research Capital LLCas of 31 Mar 2024 | 11.98k | 0.08% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.27k | 0.02% |
| U.S. Bank NA (Cincinnati Ohio Investment Management)as of 31 Mar 2024 | 500.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 122.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
